Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc's focus on developing transformative therapies for rare, monogenic central nervous system disorders has positioned the company favorably within the genetic medicines sector. Recent interim data has demonstrated sustained mean cerebrospinal fluid PGRN increases, indicating the potential for enhanced efficacy of their lead product, PBFT02, and suggesting a probable advantage over competing treatments due to a streamlined dosing procedure. Moreover, the possibility of securing regulatory alignment for accelerated approval based on biomarker endpoints could significantly reduce trial timelines, potentially enhancing future revenue prospects and overall company valuation.

Bears say

Passage Bio Inc faces significant challenges that contribute to a negative outlook on its stock, primarily associated with the inherent risks in clinical developments and potential safety issues with its gene therapy programs, namely PBGM01 and PBFT02. There are concerns regarding possible delays in clinical timelines and emerging safety signals that could adversely affect market sentiment and result in downward revisions to the company's financial forecasts. Additionally, uncertainties surrounding manufacturing capacity could further constrain the company's expected growth and operational capabilities, highlighting a precarious financial position amid the competitive landscape of genetic medicines.

PASSAGE BIO (PASG) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PASSAGE BIO (PASG) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.